MAPT and Alzheimer disease: We recently demonstrated that ponatinib and dabrafenib could rescue neuronal loss in both the preclinical xenograft model of AD as well as in a mouse model harboring both amyloid and Tau pathology (double transgenic mice, APP23xTau58) [11, 87, 119].